Abstract PO-49: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B-cell lymphomas
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/2643-3249.lymphoma20-po-49
Abstract: Introduction: Constitutive activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NF κB) pathway is a clear driver of B-cell lymphomas, especially the aggressive activated B-cell (ABC) subtype of diffuse large B-cell lymphoma… read more here.
Keywords: dlbcl; malt1; cell; jnj 67856633 ... See more keywords